Immutep Limited Stock Nasdaq
Stocks
IMMP
US45257L1089
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
00:00:00 28/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.3808 USD | +0.21% |
|
-2.63% | -86.69% |
| 07-15 | Immutep highlights encouraging survival data and key clinical milestones | FI |
| 07-14 | Immutep Granted New US Patent for Cancer Treatment Methods | MT |
| Market Cap | 73.69M 53M 45.5M 42.6M 39.01M 73.48M 5.06B 504M 197M 2.55B 199M 195M 8.44B | P/E 2026 * |
-1.29x | P/E 2027 * | -1.84x |
|---|---|---|---|---|---|
| Enterprise Value | 8.69M 6.25M 5.36M 5.02M 4.6M 8.66M 597M 59.47M 23.25M 301M 23.46M 22.96M 996M | EV / Sales 2026 * |
0.5x | EV / Sales 2027 * | -1.11x |
| Free-Float |
96.98% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +0.21% | ||
| 1 week | -2.63% | ||
| Current month | -0.31% | ||
| 1 month | -0.65% | ||
| 3 months | -12.38% | ||
| 6 months | -86.40% | ||
| Current year | -86.69% |
| 1 week | 0.37 |  | 0.4 |
| 1 month | 0.36 | | 0.41 |
| Current year | 0.29 | | 3.23 |
| 1 year | 0.29 | | 3.53 |
| 3 years | 0.29 | | 3.53 |
| 5 years | 0.29 | | 5 |
| 10 years | 0.29 | | 7.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 53 | 09/07/2014 |
David Fang
DFI | Director of Finance/CFO | - | 01/03/2018 |
Stephan Winckels
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Voigt
BRD | Director/Board Member | 53 | 09/07/2014 |
Russell Howard
CHM | Chairman | 76 | 17/11/2017 |
Pete Meyers
BRD | Director/Board Member | 57 | 12/02/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.21% | -2.63% | - | - | 54.92M | |
| +0.10% | +0.44% | +2.80% | +24.32% | 50.96B | |
| +2.65% | +4.45% | +481.36% | +567.32% | 46.18B | |
| -0.88% | +0.90% | +24.11% | +87.74% | 42.73B | |
| +0.33% | +2.47% | +38.97% | +19.80% | 43.04B | |
| -2.27% | -3.02% | +14.22% | +51.50% | 33.48B | |
| -1.21% | -0.17% | +29.16% | +135.38% | 17.28B | |
| -0.36% | -2.14% | - | - | 16.43B | |
| +0.25% | +0.25% | +12.03% | +30.68% | 14.73B | |
| +0.44% | +1.70% | +82.07% | +47.92% | 14.09B | |
| Average | -0.07% | +0.34% | +85.59% | +120.58% | 30.99B | |
| Weighted average by Cap. | +0.04% | +0.57% | +104.35% | +141.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 17.23M 12.4M 10.64M 9.96M 9.12M 17.18M 1.18B 118M 46.12M 597M 46.54M 45.54M 1.97B | 3.16M 2.27M 1.95M 1.82M 1.67M 3.15M 217M 21.61M 8.45M 109M 8.53M 8.34M 362M |
| Net income | -58.54M -42.11M -36.14M -33.84M -30.99M -58.37M -4.02B -401M -157M -2.03B -158M -155M -6.71B | -47.05M -33.84M -29.05M -27.2M -24.91M -46.92M -3.23B -322M -126M -1.63B -127M -124M -5.39B |
| Net Debt | -65M -46.75M -40.13M -37.57M -34.41M -64.81M -4.47B -445M -174M -2.25B -176M -172M -7.45B | -77.18M -55.52M -47.66M -44.62M -40.85M -76.96M -5.3B -528M -207M -2.67B -208M -204M -8.84B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/08/26 | $0.3808 | +0.21% | 130,661 |
| 26/08/26 | $0.3800 | -0.50% | 35,491 |
| 25/08/26 | $0.3819 | -1.06% | 58,397 |
| 24/08/26 | $0.3860 | -0.03% | 203,261 |
| 21/08/26 | $0.3861 | -1.28% | 113,891 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IMM Stock
- IMMP Stock
Select your edition
All financial news and data tailored to specific country editions
